Customer Publication

Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer

Authors: A. Suraweera et al.

Journal: British Journal of Cancer (2020)

Institution: Queensland University of Technology

Research Areas: Cancer research

Cell Lines: HBEC3-KT, H460, H1975, CRL5889 (HBEC3-KT, H460, H1975, CRL5889)

Summary: Despite current advances in cancer therapy, novel therapeutic targets and cancer therapies are needed to improve non-small lung patient prognosis and treatment. In this study, A. Suraweera with colleagues has identified that COMMD4 protein, which controls DNA transcription protein, can also function as a prognostic factor in non-small lung cancer and can be a therapeutic target. Authors have used HoloMonitor M4 to study cell proliferation changes after COMMD4 gene depletion.

Keywords: HoloMonitor M4, Cell proliferation, Non-small cell lung cancers, COMMD4

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2